PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1485259
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1485259
Bioanalytical Testing Services Market - By Molecule Type (Small, Large), Test Type (DMPK, Biomarker, Virology, Serology, Immunogenicity Testing), Application (Oncology, Neurology, Cardiology), By End-use & Forecast, 2024 - 2032
Bioanalytical testing services market will grow at over 8.6% CAGR between 2024 and 2032, driven by the increasing prevalence of chronic diseases and the growing demand for personalized medicine. As per WHO, every year, 41 million individuals succumb to chronic diseases, accounting for 74% of all fatalities worldwide. As pharmaceutical and biotechnology companies continue to develop innovative drugs and therapies, there is a growing requirement for bioanalytical testing to assess drug efficacy, safety, and pharmacokinetics.
Furthermore, advancements and innovations in bioanalytical testing methodologies have largely surged. The emergence of advanced analytical techniques, such as liquid chromatography-mass spectrometry (LC-MS), high-performance liquid chromatography (HPLC), and immunoassays will also significantly enhance the accuracy, sensitivity, and speed of bioanalytical testing processes.
The industry is classified based on molecule type, test type, application, end-use and region
By application, the bioanalytical testing services market from the neurology segment will witness 8.9% CAGR during 2024 and 2032. The increasing prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis has heightened the demand for accurate and comprehensive diagnostic and monitoring solutions. Bioanalytical testing services also play a critical role in supporting neurology research and drug development by providing valuable insights into disease mechanisms, biomarker identification, and therapeutic efficacy.
Bioanalytical testing services industry from the contract research organizations (CROs) end-use segment is anticipated to witness 8.7%CAGR throughout 2024 and 2032. These healthcare settings offer specialized expertise, state-of-the-art facilities, and a wide range of bioanalytical testing services for enabling pharmaceutical, biotechnology, and medical device companies to outsource their R&D activities cost-effectively. By partnering with CROs, companies can access a broader array of bioanalytical testing capabilities, including method development, validation, sample analysis, and data interpretation, without the need for significant investment in infrastructure and resources.
Europe bioanalytical testing services industry is anticipated to grow at an 8.9% CAGR over 2024-2032, attributed to the increasing investment in pharmaceutical and biotechnology R&D activities. Moreover, stringent regulatory guidelines and the need for compliance with safety and quality standards is increasing the demand for reliable and accredited bioanalytical testing services. Rising technological advancements in analytical techniques and automation streamline workflows will further stimulate the regional industry growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increased trend of outsourcing laboratory testing services
- 3.2.1.2 Rising advancements in bioanalytical technology
- 3.2.1.3 Growing drug development and approval processes
- 3.2.1.4 Increasing volume of ongoing research activities and clinical trials
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Complex regulatory framework for maintaining laboratories
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Molecule Type, 2018 - 2032 ($ Million)
- 5.1 Key trends
- 5.2 Small molecule
- 5.3 Large molecule
Chapter 6 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Million)
- 6.1 Key trends
- 6.2 DMPK testing
- 6.3 Biomarker testing
- 6.4 Virology testing
- 6.4.1 In-vivo virology testing
- 6.4.2 In-vitro virology testing
- 6.5 Serology testing
- 6.6 Immunogenicity testing
- 6.7 Other test types
Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Million)
- 7.1 Key trends
- 7.2 Oncology
- 7.3 Neurology
- 7.4 Infectious diseases
- 7.5 Gastroenterology
- 7.6 Cardiology
- 7.7 Other applications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Million)
- 8.1 Key trends
- 8.2 Pharmaceutical & biotechnology companies
- 8.3 Contract research organizations
- 8.4 Research & academic institutes
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 BioAgilytix
- 10.2 Charles River Laboratories, Inc.
- 10.3 Eurofins Scientific
- 10.4 Frontage Labs
- 10.5 ICON Plc
- 10.6 Intertek Group Plc
- 10.7 Labcorp Drug Development
- 10.8 Pace Analytical Services LLC
- 10.9 SGS Société Générale de Surveillance SA
- 10.10 Syneos Health
- 10.11 Thermo Fisher Scientific Inc.
- 10.12 WuXi AppTec
